Skip to main content

Francesca Reale, Roby Attal join ‘This Summer Will Be Different’ Netflix series adaptation

A photo of Francesca Reale. (Ian Lipton) | A photo of Roby Attal. (Chris Labadie)

This Summer Will Be Different has gained a couple more cast members.

Netflix has announced that Francesca Reale and Roby Attal have joined the cast of the upcoming TV adaptation of author Carley Fortune’s bestselling romance novel.

Reale is set to play Bridget in the show, while Attal will take on the role of Felix, who also goes by the nickname Wolf. They join the previously announced star Sophie Nélisse, who is set to play Lucy.

This Summer Will Be Different will be “a simmering, sun-soaked romance set across multiple summers on Prince Edward Island about Lucy, a young woman navigating her 20s and her first real love with her best friend’s brother, the one person she was never supposed to fall for,” according to the show’s logline.

Dane Clark and Linsey Stewart serve as the adaptation’s creators and showrunners. They also both executive produce the show alongside Fortune.

This Summer Will Be Different will film on location in Prince Edward Island and in Toronto. It will span 10 episodes.

“I fell in love with Prince Edward Island first in the pages of L.M. Montgomery’s Anne of Green Gables and again when I visited with my best friend in my early 20s,” Fortune told Netflix. “That vacation, the beauty of the island, the warmth of its people, and the friendships that sustain us are the foundation of This Summer Will Be Different. I’m thrilled to bring this sweeping love story to the screen with Netflix and to transport audiences to the glittering shores and windswept beaches of PEI.”

Reale is known for her appearance in the third season of Stranger Things. Attal was most recently seen in recurring roles in Dexter: Original Sin and The Sex Lives of College Girls.

Copyright © 2026, ABC Audio. All rights reserved.

Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial

Stock photo of a doctor examining a patient's skin. (Lordhenrivoton/STOCK PHOTO/Getty Images)(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients whose high-risk melanoma had been surgically removed.The combination treatment regimen pairs the personalized vaccine with Merck's Keytruda, which had previously been used to treat the cancer alone.The treatment showed a 49% reduction of melanoma return after patients underwent surgery and a 59% reduction of metastasization of the cancer to distant organs.Key questions surrounding regulatory review of the vaccine remain.The Food and Drug Administration has not yet approved the vaccine. The agency will review the full data once it has been collected and submitted.While the FDA has already approved other cancer vaccines, this new treatment represents a step forward in the field as it uses mRNA technology and personalized treatment for each patient.Merck and Moderna plan to present data at an upcoming international medical meeting where they hope to engage regulators on filing submissions for approval of the regimen, the companies said in a joint press release.Dr. Ahmad Tarhini, an oncologist at the H. Lee Moffitt Cancer Center & Research Institute, told ABC News that he expects the treatment to be approved based on very positive trial results and made available to patients likely by early 2027.The vaccine uses genetic information from patients' individual tumors to identify and attack the cancer."It's what we call individualized neoantigen therapy, where we take the cancer itself, we do genetic sequencing and try to define a unique mutational fingerprint of the cancer itself," Tarhini said.Melanoma is the deadliest form of skin cancer, with about 112,000 new cases expected in 2026, according to the American Cancer Society.The treatment is considered relatively safe, according to the companies. The most common side effects include fatigue, sore arm and chills.Treatments utilizing mRNA technologies are being used in trials for other forms of cancer, including that of the bladder, kidney, lungs, stomach and pancreas, according to Tarhini."I think it will certainly improve the outcome of our patients," Tarhini said. "We are, you know, excited about this development. My expectation is this will eventually change the standard care of our patients."Copyright © 2026, ABC Audio. All rights reserved.
Read Next Story

Related Stories

Latest News
Moving pillowcase leads to discovery of reptiles in car seized at border
10 minutes ago

Moving pillowcase leads to discovery of reptiles in car seized at border

Suburban man found with Molotov cocktails released on electronic monitoring by judge

FAA investigating after 3 planes had tires blown out at O'Hare Airport

Pan Am Flight 103 Fast Facts

Renée Richards demandó para convertirse en la primera mujer trans en jugar tenis femenino. Hoy piensa diferente